APA (7th ed.) Citation

Yu, Q., Li, R., Li, Z., Wan, Z., Lv, K., He, C., . . . Zhao, M. (2026). Dehydrocorydaline Exerts Anti-Pancreatic Cancer Effects Through the PI3K/Akt/mTOR Pathway. Pharmaceuticals (14248247), 19(6), 864. https://doi.org/10.3390/ph19060864

Chicago Style (17th ed.) Citation

Yu, Qingmeng, et al. "Dehydrocorydaline Exerts Anti-Pancreatic Cancer Effects Through the PI3K/Akt/mTOR Pathway." Pharmaceuticals (14248247) 19, no. 6 (2026): 864. https://doi.org/10.3390/ph19060864.

MLA (9th ed.) Citation

Yu, Qingmeng, et al. "Dehydrocorydaline Exerts Anti-Pancreatic Cancer Effects Through the PI3K/Akt/mTOR Pathway." Pharmaceuticals (14248247), vol. 19, no. 6, 2026, p. 864, https://doi.org/10.3390/ph19060864.